U.S. Capital Wealth Advisors LLC Raises Holdings in GSK plc (NYSE:GSK)

U.S. Capital Wealth Advisors LLC boosted its stake in shares of GSK plc (NYSE:GSK) by 0.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 243,045 shares of the pharmaceutical company’s stock after buying an additional 1,072 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in GSK were worth $9,936,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eastern Bank purchased a new stake in shares of GSK during the 3rd quarter worth $26,000. Sequoia Financial Advisors LLC raised its holdings in GSK by 2.6% in the third quarter. Sequoia Financial Advisors LLC now owns 22,937 shares of the pharmaceutical company’s stock worth $938,000 after purchasing an additional 577 shares in the last quarter. Foundations Investment Advisors LLC lifted its position in shares of GSK by 4.8% during the third quarter. Foundations Investment Advisors LLC now owns 10,122 shares of the pharmaceutical company’s stock valued at $414,000 after buying an additional 466 shares during the last quarter. Ledyard National Bank boosted its holdings in shares of GSK by 24.1% in the 3rd quarter. Ledyard National Bank now owns 24,281 shares of the pharmaceutical company’s stock valued at $993,000 after buying an additional 4,712 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of GSK by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock worth $481,000 after buying an additional 3,405 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Insider Activity at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.00% of the stock is currently owned by insiders.

GSK Stock Performance

Shares of NYSE GSK traded down $0.22 during mid-day trading on Wednesday, hitting $37.78. The stock had a trading volume of 2,414,568 shares, compared to its average volume of 3,730,449. The firm has a market cap of $78.30 billion, a PE ratio of 13.77, a PEG ratio of 1.30 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The company has a 50 day moving average of $41.33 and a two-hundred day moving average of $41.21. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. Research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were issued a dividend of $0.3843 per share. This represents a $1.54 annualized dividend and a dividend yield of 4.07%. The ex-dividend date was Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 55.80%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GSK shares. Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Jefferies Financial Group raised their price objective on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.